Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals has cancelled 6,928,586 fully paid ordinary shares following an employee share scheme buy-back, effective 29 December 2025. The reduction in issued capital marginally tightens the company’s share base and may have implications for existing shareholders by modestly improving per-share metrics and signalling active management of its employee equity programs.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australian-listed pharmaceutical company (ASX: BOT) operating in the life sciences sector, focused on developing and commercialising therapeutic products. The company typically concentrates on prescription treatments, leveraging clinical development capabilities to address unmet medical needs in its targeted markets.
Average Trading Volume: 5,606,992
Technical Sentiment Signal: Sell
Current Market Cap: A$237M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.